Activation of the MET receptor attenuates doxorubicin-induced cardiotoxicity in vivo and in vitro.

Simona GalloMartina SpilingaRaffaella AlbanoGiuseppe FerrautoEnza Di GregorioElena CasanovaDavide BalmativolaAlessandro BonzanoCarla BoccaccioAnna SapinoPaolo Maria ComoglioTiziana Crepaldi

Published in: British journal of pharmacology (2020)

The MET agonist mAb provides a new tool for cardioprotection against anthracycline cardiotoxicity.

Keyphrases

tyrosine kinase
high glucose
diabetic rats
drug delivery
drug induced
cancer therapy
oxidative stress
binding protein
stress induced